Trial Profile
A PHASE III, MULTICENTRE, DOUBLE BLIND, PROSPECTIVE, RANDOMISED, PLACEBO CONTROLLED STUDY, ASSESSING THE EFFICACY AND SAFETY OF DYSPORT USED FOR THE TREATMENT OF LOWER LIMB SPASTICITY IN ADULT SUBJECTS WITH HEMIPARESIS DUE TO STROKE OR TRAUMATIC BRAIN INJURY
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Aug 2019
Price :
$35
*
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Muscle spasticity
- Focus Registrational; Therapeutic Use
- Sponsors Ipsen
- 27 Apr 2018 Results from NCT01249404 and the extension study NCT01251367, presented at the 70th Annual Meeting of the American Academy of Neurology
- 23 Apr 2018 Results presented in an Ipsen Biopharmaceuticals media release.
- 23 Apr 2018 According to an Ipsen Biopharmaceuticals media release, data from this study will be presented at the American Academy of Neurology (AAN) 2018.